Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfenex Pitches Teriparatide Pen Against Lilly's Forteo as Partner Alvogen Files In Europe

Executive Summary

Alvogen is conducting a study directing comparing its teriparatide delivery device with that of Lilly’s Forteo in a bid to be substitutable in the US for Pfizer’s original. The firm’s partner, Alvogen, has just filed the osteoporosis drug under Europe’s centralized procedure.



Related Content

Rovi Rolls Out Enoxaparin In Portugal As It Prepares For Teriparatide
Alvogen And Pfenex Broaden Teriparatide Collaboration
Gedeon Richter Predicts Two-Year Wait To Refile Pegfilgrastim, But Teriparatide Is In The Wings


Related Companies

What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts